Investigator
Cleveland Clinic
Fam-Trastuzumab Deruxtecan in HER2/Neu-Expressing Serous Endometrial Cancer
Trastuzumab deruxtecan treatment of 3 patients with HER2/neu-expressing serous endometrial cancer resulted in objective response